President and CEO, Randy Hubbell, will present at the 21st Annual BIO CEO & Investor Conference on Monday, February 11th at 1:45 p.m. in the Chelsea presentation room at the New York City Marriot Marquis.
Hubbell will discuss Carmell’s latest corporate milestones, including Phase III clinical trial enrollment plans for their flagship Bone Healing Accelerant product. He will also provide insights into the current state of the orthobiologics field, including key differentiators for Carmell’s technology, market opportunities and current FDA regulatory trends.
“We are excited for the opportunity to present at this year’s BIO CEO & Investor Conference,” said Randy Hubbell, President and CEO of Carmell Therapeutics. “We are looking forward to updating our corporate and clinical progress to stakeholders and potential partners, as well as communicating the transformational potential of our platform, which is uniquely suited for multiple high-value medical indications.”
The company’s Plasma-based Bioactive Materials (PBMs) platform is designed to improve patient outcomes and reduce healthcare costs across a variety of surgical procedures. This technology is based on biologically-active materials manufactured from human blood plasma, containing natural regenerative factors that promote healing in various clinical settings. Carmell has patented a process which allows for the controlled, staged release of regenerative factors to promote faster healing.
About Carmell Therapeutics
Carmell Therapeutics (Carmell) is addressing the burden of bone and tissue healing with its proprietary Plasma-based Bioactive Materials (PBM) technology, designed to improve patient outcomes and reduce health care costs. Carmell’s novel approach takes whole platelet-rich plasma, processes it in a manner that retains its regenerative properties, and delivers it to the injured site in a controlled-release capacity for faster, more effective healing. For more information, please visit www.carmellrx.com
About Carmell’s PBM Technology Platform
Carmell Therapeutics’ unique PBM technology platform can be delivered in multiple formats to the site of injury – from putties to pastes to surgical screws. A proprietary manufacturing process ensures safety and that bioactive regenerative factors are delivered in a time-released manner for optimal healing. Carmell currently has two PBM products in development – a Bone Healing Accelerant and Tissue Healing Accelerant.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190204005360/en/
Contacts
LaVoieHealthScience
Anthony Karamourtopoulos
O: 617-374-8800 x104
M: 617-792-3540
akara@lavoiehealthscience.com
Source: Carmell Therapeutics
View this news release online at:
http://www.businesswire.com/news/home/20190204005360/en
